Exagen Inc (NASDAQ: XGN)’s stock price has plunge by -9.81relation to previous closing price of 6.83. Nevertheless, the company has seen a 0.33% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-08 that CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3,350,000 shares of its common stock at a public offering price of $5.25 per share.
Is It Worth Investing in Exagen Inc (NASDAQ: XGN) Right Now?
XGN has 36-month beta value of 1.59. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for XGN is 9.22M, and currently, short sellers hold a 0.66% ratio of that float. The average trading volume of XGN on May 09, 2025 was 129.83K shares.
XGN’s Market Performance
XGN’s stock has seen a 0.33% increase for the week, with a 54.00% rise in the past month and a 16.89% gain in the past quarter. The volatility ratio for the week is 13.41%, and the volatility levels for the past 30 days are at 11.30% for Exagen Inc The simple moving average for the past 20 days is 10.90% for XGN’s stock, with a 67.72% simple moving average for the past 200 days.
Analysts’ Opinion of XGN
Cowen, on the other hand, stated in their research note that they expect to see XGN reach a price target of $26. The rating they have provided for XGN stocks is “Outperform” according to the report published on October 15th, 2021.
Canaccord Genuity gave a rating of “Buy” to XGN, setting the target price at $25 in the report published on April 15th of the previous year.
XGN Trading at 38.92% from the 50-Day Moving Average
After a stumble in the market that brought XGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.44% of loss for the given period.
Volatility was left at 11.30%, however, over the last 30 days, the volatility rate increased by 13.41%, as shares surge +40.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +75.00% upper at present.
During the last 5 trading sessions, XGN rose by +0.33%, which changed the moving average for the period of 200-days by +220.83% in comparison to the 20-day moving average, which settled at $5.55. In addition, Exagen Inc saw 50.24% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XGN starting from NMSIC Co-Investment Fund, L.P., who sale 350,000 shares at the price of $3.30 back on Mar 25 ’25. After this action, NMSIC Co-Investment Fund, L.P. now owns 1,758,958 shares of Exagen Inc, valued at $1,155,000 using the latest closing price.
NMSIC Co-Investment Fund, L.P., the 10% Owner of Exagen Inc, sale 200,000 shares at $3.30 during a trade that took place back on Nov 20 ’24, which means that NMSIC Co-Investment Fund, L.P. is holding 2,108,958 shares at $660,040 based on the most recent closing price.
Stock Fundamentals for XGN
Current profitability levels for the company are sitting at:
- -0.25 for the present operating margin
- 0.59 for the gross margin
The net margin for Exagen Inc stands at -0.27. The total capital return value is set at -0.53. Equity return is now at value -117.50, with -34.04 for asset returns.
Based on Exagen Inc (XGN), the company’s capital structure generated 0.44 points at debt to capital in total, while cash flow to debt ratio is standing at -2.96. The debt to equity ratio resting at 0.79. The interest coverage ratio of the stock is -12.28.
Currently, EBITDA for the company is -11.14 million with net debt to EBITDA at 0.51. When we switch over and look at the enterprise to sales, we see a ratio of 1.85. The receivables turnover for the company is 3.85for trailing twelve months and the total asset turnover is 1.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.32.
Conclusion
To put it simply, Exagen Inc (XGN) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
